Continued media coverage of the OHSU-Legacy Health integration announcement.

In a story about simultaneous flares of the skin disorder psoriasis and its related joint disorder, psoriatic arthritis, Atul Deodhar, M.D., notes the drug methotrexate can treat symptoms of both disorders.

A segment about queer people migrating to Oregon from states that are less welcoming to LGBTQIA+ community members, includes a statement from OHSU: “As other states have recently moved to limit or ban gender-affirming health care, the OHSU Transgender Health Program has anecdotally noticed an increase in inquiries from people living in other states and more referrals being submitted on behalf of those who are moving to Oregon. While OHSU is saddened to know gender-diverse individuals are being forced to leave their home states out of fear for their health and safety, the Transgender Health Program is proud to be part of a university committed to providing care for new and long-standing patients alike as well as to be based in a state where gender-affirming care coverage is being protected and expanded.”

In a story about limited access to weight-loss prescription medications, Jonathan Purnell, M.D., advises against obtaining medications formulated at compounding pharmacies and notes that anti-fat bias can make some health providers reluctant to prescribe these medications.

In a BusinessWire press release from Scale Biosciences on the expansion of their product portfolio to enable a broader range of single cell omics experiments, Andrew Adey, Ph.D., says "The research community needs a robust solution to scale single cell methylation analysis and help unlock new understandings of the relationship between genomics, epigenetics and human health.”

Researchers at Oregon State University and OHSU are testing a way to deliver treatment for ectopic pregnancies in a far more targeted way.

Continued coverage on a first-known study led by Bethany Samuelson Bannow, M.D., finds many menstrual products had a much lower or higher liquid capacity than advertised when real blood was used instead of a saline solution more commonly employed in the product development process.

In an Atsena Therapeutics press release announcing the first dose being given for a clinical trial evaluating an experimental gene therapy for the vision-threatening condition retinitis pigmentosa, Mark Pennesi, M.D., Ph.D., says: "Considering the lack of available therapies for X-linked retinoschisis, this is very exciting news for the inherited retinal disease community.”

An OPB News story profiles Doernbecher Children's Hospital's Therapeutic Gaming Program, designed to help children cope with stressful places like hospitals. The program is led by Sam Giles LeBlanc who says: “If you’re stuck in a hospital bed all day every day, then to have this feeling of a whole world that you can explore, you know, it’s like books, but on a different level because you’re personally exploring that world.”

Continued coverage on a first-known study led by Bethany Samuelson Bannow, M.D., finds many menstrual products had a much lower or higher liquid capacity than advertised when real blood was used instead of a saline solution more commonly employed in the product development process.